Skip to main content
Premium Trial:

Request an Annual Quote

Regulus Says USPTO Allows Claims in miRNA-Related Patent Application

Premium

Regulus Therapeutics, a microRNA drugs joint venture between Isis Pharmaceuticals and Alnylam Pharmaceuticals, said this week that it has been notified that the US Patent and Trademark Office has allowed a patent application within one of the company's patent families.

The patent application, No. 20050261218 and titled "Oligomeric Compounds and Compositions for Use in Modulation [of] Small Non-Coding RNAs," claims methods of inhibiting the liver-specific miRNA miR-122, which has been shown to play a role in hepatitis C virus replication.

"Specifically, the claims encompass methods of inhibiting miR-122 in a cell using a broad class of [miRNA antagonists] with sugar modifications at each nucleoside, such as 2'-MOE or bicyclic nucleic acid modifications, and with or without the addition of conjugate groups," the company said.

The company said it expects the patent office to issue a final patent on the application within a year.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.